Tags: Drug.

TM38837 is a new small molecule inverse agonist/antagonist of the CB1 cannabinoid receptor. It is being developed for the treatment of obesity and metabolic disorders by 7TM Pharma. The company has announced phase I clinical trials.TM38837 is among the first of a new generation of cannabinoid receptor antagonist designed to avoid the central nervous system liabilities of the first generation CB1 receptor antagonists for example rimonabant.

TM-38837.svg
ATC prefix
none
IUPAC name
1-(24-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide
PubChem
49779607

Loading...

This page contains content from the copyrighted Wikipedia article "TM-38837"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.